Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glepaglutide in Short Bowel Syndrome (EASE SBS 1)
NCT03690206Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Oct 2018
- Primary completion
- Jul 2022
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of glepaglutide in short bowel syndrome (SBS) (3 arms), sponsored by Zealand Pharma. Primary endpoint: Change in Weekly Parenteral Support (PS) Volume at 24 weeks. Started Oct 2018; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03690206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690206.